Susquehanna International Group’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-31,300
| Closed | -$228K | – | 12300 |
|
|
2025
Q3 | $228K | Buy |
+31,300
| New | +$212K | ﹤0.01% | 10707 |
|
|
2024
Q2 | – | Sell |
-424,100
| Closed | -$5.97M | – | 12006 |
|
|
2024
Q1 | $5.97M | Buy |
+424,100
| New | +$5.28M | ﹤0.01% | 3356 |
|
|
2023
Q3 | – | Sell |
-16,100
| Closed | -$134K | – | 11983 |
|
|
2023
Q2 | $134K | Sell |
16,100
-1,700
| -10% | -$19.6K | ﹤0.01% | 10684 |
|
|
2023
Q1 | $237K | Buy |
+17,800
| New | +$241K | ﹤0.01% | 10231 |
|
|
2022
Q3 | – | Sell |
-61,900
| Closed | -$186K | – | 13127 |
|
|
2022
Q2 | $186K | Sell |
61,900
-118,600
| -66% | -$532K | ﹤0.01% | 10741 |
|
|
2022
Q1 | $1.21M | Sell |
180,500
-36,000
| -17% | -$214K | ﹤0.01% | 6637 |
|
|
2021
Q4 | $1.17M | Buy |
216,500
+196,800
| +999% | +$1.29M | ﹤0.01% | 6890 |
|
|
2021
Q3 | $174K | Buy |
19,700
+15,600
| +380% | +$149K | ﹤0.01% | 11641 |
|
|
2021
Q2 | $52K | Sell |
4,100
-9,917
| -71% | -$129K | ﹤0.01% | 12287 |
|
|
2021
Q1 | $243K | Buy |
14,017
+5,117
| +57% | +$92.4K | ﹤0.01% | 11048 |
|
|
2020
Q4 | $114K | Sell |
8,900
-5,950
| -40% | -$106K | ﹤0.01% | 10431 |
|
|
2020
Q3 | $552K | Buy |
14,850
+4,067
| +38% | +$161K | ﹤0.01% | 7463 |
|
|
2020
Q2 | $416K | Buy |
+10,783
| New | +$384K | ﹤0.01% | 7753 |
|
Susquehanna International Group's ATXS Position: Q1 2026 in Review
Susquehanna International Group sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 36,322 shares — an estimated $475K sold.
Susquehanna International Group first reported a position in ATXS in Q3 2015 and held it in 17 quarters. The position peaked at $2.92M in Q1 2023. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Susquehanna International Group reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Susquehanna International Group sold 36,322 Astria Therapeutics shares in Q1 2026, an estimated $475K.
- Susquehanna International Group first reported a position in Astria Therapeutics in Q3 2015 and held it in 17 quarters.
- Susquehanna International Group's Astria Therapeutics position peaked at $2.92M in Q1 2023.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.